Microangiopathic Ulcers of the Lower Extremities: A Daily Challenge
O ne of the main routine problems of cutaneous ulcer care is to make an appropriate diagnosis and to assess the specific role of microvascular compromise in the pathogenesis of a single ulcer. As an example, the venous hypertensive microangiopathy is thought to play a central role in venous ulcer formation, but up to now, different theories have been proposed that only partially explain the intimal mechanism of the cutaneous damage. 1 Moreover, they do not completely throw light on the individual variable response to apparently similar conditions of altered venous refluxes due to chronic venous insufficiency.
A well-known group of primitively microangiopathic diseases accounts for 4% to 6% of lower limb ulcers. 2 It includes several disorders that compromise microvessels and specifically the cutaneous vascular system: arterioles, capillaries, and postcapillary venules. They may associate or complicate other ulcer-predisposing disturbances (ie, chronic venous insufficiency, neuroischemic disorders) and provide explanations for nonhealing ulcers or delayed tissue repair.
The clinical manifestations are the expression of the size and the severity of the vessel injury. The intensity and duration of the cutaneous tissue ischemia can result in skin necrosis and ulcer formation. In many cases, the ulcers are multiple and localize in the leg and foot where the microcirculatory anatomy and the rheologic dynamics favor ulcer formation.
Considering the pathogenesis, it is possible to distinguish 2 main groups of ulcers due to microangiopathic disorders: inflammatory and occlusive. Occasionally they may overlap such as in cryoproteinmediated vessel injury.
A number of inflammatory ulcers are the outcome of a vasculitic process. Vasculitis is an immunologically mediated angiocentric inflammation, characterized by infiltration of neutrophils and lympho-monocytes, fibrinoid necrosis of the vessel walls, and extravasation of red cells. It may result in the destruction, thrombosis, or fibrosis of the vessel; reduction of tissue blood supply; and ischemia. The current classification divides them into small-, medium-, and large-vessel vasculitis. 3 Connective tissue diseases, pyoderma gangrenosum, and cutaneous infectious diseases can be responsible for a smaller number of inflammatory ulcers. 4 The group of microangiopathic occlusive ulcers is more heterogeneous and includes very poorly understood disturbances (such as livedo vasculopathy 5 and calciphylaxis), still debated ulcerative diseases (such as hypertensive ulcers), recently described iatrogenic ulcers (ie, during hydroxyurea therapy), ulcers due to the deposition of cryoprotein, ulcers linked to clot formation (ie, antiphospholipid antibodies) or microembolization (ie, cholesterol emboli, injected substances), and metabolic anomalies. 6 These conditions can induce thromboses or anatomic, and therefore functional, occlusion of cutaneous microvessels. All microvascular disorders need a specific diagnosis and an adequate therapy.
There are problems that we consider in the routine care of such patients. The first is to suspect the microvascular ulcerative disease and to differentiate from other types of more common ulceration. If we are lucky, the clinical features may help us, being often, at onset, multiple necrotizing lesions more or less associated with concomitant skin signs such as palpable purpura, livedo reticularis, or retiform purpura. Difficulties may arise when we first see the patient with long-lasting or evolved ulcers that have clinical features that are very similar ulcers but in fact have a different pathogenesis.
Palpable purpura is typical of vasculitis and is the expression of vessel inflammation. Livedo reticularis (LR) reflects the physiologic anatomy of slow flow conditions. The bluish network-like pattern of LR may range from 3 cm to 4 to 5 cm in relation to the different involved cutaneous areas. Retiform purpura (RP) derives from the microvessel occlusion of the districts with livedo reticularis. 7 The hemorrhage responsible for purpura is probably prior to complete occlusion of the vessel. LR and RP are prevalently seen in microvascular occlusive syndromes but may be sometimes present as a clinical end-result of the occlusive complication of a vasculitic process (ie, anti-neutrophilic cytoplasmic antibody-positive vasculitis, cutaneous pan arteritis nodosa). A special mention must be made of pyoderma gangrenosum (PG), which is a neutrophil-mediated inflammatory ulcer that is frequently associated with internal diseases. 2 Specific clinical findings, such as violaceous submined ulcerative borders, are the markers of the disease. They may not be present continuously but may be seen during active phases of PG.
The second problem is to confirm the clinical suspicion. It goes through an adequate anamnesis and laboratory tests such as immunological assessment for vasculitis or connective tissue disease-related ulcers 8 and extensive coagulative system examination, mainly for occlusive microangiopathies. It is also based on a systemic laboratory and instrumental assessment of the risk for internal vasculopathies that can be associated with cutaneous lesions. 9 Macrocirculatory examination using duplex ultrasonography is mandatory. It may help the therapeutic strategies when an associated large-vessel disturbance is found.
Last, as the skin is an easy field of investigation, a biopsy should be performed for histological examination. A sample from a recent lesion or possibly at a peripheral border of an actively extending ulceration should be taken. The histological diagnosis of neutrophils-mediated vasculitis or the picture of thrombotic microangiopathy may help to establish a correct systemic treatment. 10 The latter is the third and sometimes controversial problem.
Therapies for inflammatory disease differ greatly from treatments for occlusive disease. The choice of immunosuppressive or anti-inflammatory therapy for occlusive disease could be unsuccessful or eventually harmful. At the same time, the use of anticoagulant drugs may be risky in most vasculitis. The therapeutic choices have to rely on the accuracy of the diagnosis and a careful clinical observation of the phase of the disease.
In addition, some of the drugs currently used in the cure of these disorders (ie, corticosteroids, cyclophosphamyde, methotrexate, and others) have been shown to interfere with wound-healing mechanisms. Therefore, we may run the risk of curing the basic disease, such as vasculitis, but impair the ulcer healing.
The role of cutaneous microangiopathic disorders in the clinical history of a skin ulcer needs to be carefully evaluated also in the light that many recent research findings support the concept that coagulation, inflammation, and wound-healing process are actively and importantly integrated. 11
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